When a program needs breadth at scale, the economics of the laboratory matter as much as the science, and a 671-gene solid tumor panel is built for exactly that combination. It offers very large somatic coverage while running on a high-throughput platform suited to institutional volume. Sourcing it well means matching specimen flow to laboratory capacity.
The panel uses broad hybrid-capture sequencing across 671 genes to report point mutations, copy changes, and fusions from one nucleic-acid extract. Automated sample handling and parallel library preparation let many cases move through together without losing per-sample traceability. Results arrive as a comprehensive profile with tiered findings linked to therapeutic and trial options.
This large panel fits advanced solid-tumor programs, molecular tumor boards, and research cohorts that want near-exhaustive coverage. It is valuable when smaller panels have returned no actionable result and a wider search is justified. The breadth supports both immediate therapy choices and future re-analysis.
FFPE tissue or liquid biopsy is accepted, and turnaround is about 12–16 working days for the larger scope. Reports are delivered in a consistent format with a summary page for rapid review. Batch submission is encouraged to align with the platform's throughput.
Extracts travel on dry ice; FFPE scrolls ship with desiccant at ambient temperature. Minimum order quantities and scheduled batches help institutions secure capacity and predictable pricing. Give Life Time International manages reorder and logistics so high-volume programs avoid bottlenecks. A quarterly capacity plan lets large programs reserve instrument time in advance, which prevents queue buildup during peak referral periods and keeps turnaround stable for every batch. Institutions can also request consolidated monthly invoicing and a single point of contact, which simplifies procurement across multiple departments and reduces administrative overhead.
Q: What minimum volume should an institution plan for? Programs typically commit to scheduled batch sizes that match the platform's throughput; the service team advises a practical minimum order.
Q: Why choose a 671-gene panel over a smaller one? The larger scope captures rarer alterations and supports re-analysis as new associations emerge, reducing the need for repeat testing.
Q: How is per-sample traceability maintained at high throughput? Automated handling and barcoded tracking preserve identity even when many libraries run in parallel.
Q: Can batches be mixed between tissue and liquid biopsy? Yes, both specimen types are accepted within a batch, provided each meets the input requirements for the capture design.
When a program needs breadth at scale, the economics of the laboratory matter as much as the science, and a 671-gene solid tumor panel is built for exactly that combination. It offers very large somatic coverage while running on a high-throughput platform suited to institutional volume. Sourcing it well means matching specimen flow to laboratory capacity.
The panel uses broad hybrid-capture sequencing across 671 genes to report point mutations, copy changes, and fusions from one nucleic-acid extract. Automated sample handling and parallel library preparation let many cases move through together without losing per-sample traceability. Results arrive as a comprehensive profile with tiered findings linked to therapeutic and trial options.
This large panel fits advanced solid-tumor programs, molecular tumor boards, and research cohorts that want near-exhaustive coverage. It is valuable when smaller panels have returned no actionable result and a wider search is justified. The breadth supports both immediate therapy choices and future re-analysis.
FFPE tissue or liquid biopsy is accepted, and turnaround is about 12–16 working days for the larger scope. Reports are delivered in a consistent format with a summary page for rapid review. Batch submission is encouraged to align with the platform's throughput.
Extracts travel on dry ice; FFPE scrolls ship with desiccant at ambient temperature. Minimum order quantities and scheduled batches help institutions secure capacity and predictable pricing. Give Life Time International manages reorder and logistics so high-volume programs avoid bottlenecks. A quarterly capacity plan lets large programs reserve instrument time in advance, which prevents queue buildup during peak referral periods and keeps turnaround stable for every batch. Institutions can also request consolidated monthly invoicing and a single point of contact, which simplifies procurement across multiple departments and reduces administrative overhead.
Q: What minimum volume should an institution plan for? Programs typically commit to scheduled batch sizes that match the platform's throughput; the service team advises a practical minimum order.
Q: Why choose a 671-gene panel over a smaller one? The larger scope captures rarer alterations and supports re-analysis as new associations emerge, reducing the need for repeat testing.
Q: How is per-sample traceability maintained at high throughput? Automated handling and barcoded tracking preserve identity even when many libraries run in parallel.
Q: Can batches be mixed between tissue and liquid biopsy? Yes, both specimen types are accepted within a batch, provided each meets the input requirements for the capture design.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
